Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Research And Development Expense of $74.30 million for the year ending 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +7.5% in Research And Development Expense from 2024 to 2025.
- This data is from WEST PHARMACEUTICAL SERVICES INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $5.40 million | Q2 2010: $5.70 million | Q3 2010: $5.90 million | Q1 2011: $6.90 million | Q2 2011: $7.30 million | Q3 2011: $7.70 million | Q1 2012: $8.30 million | Q2 2012: $8.20 million | Q3 2012: $8.20 million | Q1 2013: $9.10 million | Q2 2013: $9.50 million | Q3 2013: $9.60 million | Q1 2014: $10.00 million | Q2 2014: $9.90 million | Q3 2014: $9.60 million | Q1 2015: $7.50 million | Q2 2015: $8.10 million | Q3 2015: $8.50 million | Q1 2016: $9.40 million | Q2 2016: $8.80 million | Q3 2016: $9.00 million | Q1 2017: $10.30 million | Q2 2017: $10.00 million | Q3 2017: $9.10 million | Q1 2018: $9.60 million | Q2 2018: $10.80 million | Q3 2018: $10.10 million | Q1 2019: $9.80 million | Q2 2019: $9.60 million | Q3 2019: $9.30 million | Q1 2020: $10.70 million | Q2 2020: $10.80 million | Q3 2020: $12.50 million | Q1 2021: $12.20 million | Q2 2021: $13.80 million | Q3 2021: $13.10 million | Q1 2022: $14.60 million | Q2 2022: $14.40 million | Q3 2022: $13.60 million | Q1 2023: $17.10 million | Q2 2023: $16.50 million | Q3 2023: $16.40 million | Q1 2024: $17.60 million | Q2 2024: $17.50 million | Q3 2024: $15.50 million | Q1 2025: $16.30 million | Q2 2025: $19.10 million | Q3 2025: $17.10 million.
- Over the full 18 years of available data (2008 to 2025), WEST PHARMACEUTICAL SERVICES INC's Research And Development Expense has grown by 297.3%.
- Historical annual values: Fiscal year 2025: $74.30 million | Fiscal year 2024: $69.10 million | Fiscal year 2023: $68.40 million | Fiscal year 2022: $58.50 million | Fiscal year 2021: $52.80 million | Fiscal year 2020: $46.90 million | Fiscal year 2019: $38.90 million | Fiscal year 2018: $40.30 million | Fiscal year 2017: $39.10 million | Fiscal year 2016: $36.80 million | Fiscal year 2015: $34.10 million | Fiscal year 2014: $37.30 million | Fiscal year 2013: $37.90 million | Fiscal year 2012: $33.20 million | Fiscal year 2011: $29.10 million | Fiscal year 2010: $23.90 million | Fiscal year 2009: $19.90 million | Fiscal year 2008: $18.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: